DecisionRx, a value-based healthcare company focused on reducing the cost of care by helping physicians optimise prescribing decisions for their patients, has agreed a a $100m credit facility with global investment firm Carlyle.
As part of the transaction, which was led by Carlyle’s credit strategic solutions team, a group within the global credit business focused on private fixed income and asset-backed investments, Carlyle has secured the option to acquire 25% of the outstanding equity of DecisionRx.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
The financing will support DecisionRx in delivering medication therapy optimisation to patients of accountable care organisations, Medicare Advantage plans, and self-insured employers. The facility is expected to fund lab testing and comprehensive medication reviews by DecisionRx pharmacists for over 100,000 patients.
Aon Securities served as an advisor to DecisionRx in arranging the financing.
Source: Private Equity Wire
Can’t stop reading? Read more
Ares raises $5.4bn for US and Europe real estate strategies as recovery drives demand
Ares raises $5.4bn for US and Europe real estate strategies as recovery drives demand Ares has...
Blue Owl caps fund withdrawals as private credit demand recalibrates amid market volatility
Blue Owl caps fund withdrawals as private credit demand recalibrates amid market volatility Blue...
Sycamore targets $4bn profit at Walgreens following $10bn buyout
Sycamore targets $4bn profit at Walgreens following $10bn buyout Sycamore Partners is targeting a...